HDM1002
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Huadong Medicine · Phase 3 · Not yet recruiting · Enrollment 780
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1002 tablets 200mg once daily | n/r | n/r | n/r | n/r |
| HDM1002 tablets 400mg once daily | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- HDM1002 tablets 200mg once daily: endpoint not reported
- HDM1002 tablets 400mg once daily: endpoint not reported
- Placebo: endpoint not reported